Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study

Saroglitazar, a dual peroxisome proliferator activated receptor α/γ agonist, approved for diabetic dyslipidemia (DD), is potential therapeutic option for non-alcoholic fatty liver disease (NAFLD). This prospective, observational, real-world study aimed to determine efficacy and safety of Saroglitaza...

Descripción completa

Detalles Bibliográficos
Autores principales: Goyal, Omesh, Nohria, Sahil, Goyal, Prerna, Kaur, Jaskirat, Sharma, Sarit, Sood, Ajit, Chhina, Rajoo Singh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7713236/
https://www.ncbi.nlm.nih.gov/pubmed/33273703
http://dx.doi.org/10.1038/s41598-020-78342-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7713236/
https://www.ncbi.nlm.nih.gov/pubmed/33273703
http://dx.doi.org/10.1038/s41598-020-78342-x

Ejemplares similares